Jason Zemansky
Stock Analyst at B of A Securities
(4.60)
# 144
Out of 4,829 analysts
34
Total ratings
65.22%
Success rate
27.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Neutral | $62 → $54 | $32.13 | +68.07% | 4 | Apr 15, 2025 | |
| INSM Insmed | Maintains: Buy | $92 → $96 | $67.75 | +41.70% | 9 | Mar 20, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $8.80 | +93.18% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $6.09 | +376.58% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $10.99 | +182.07% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $0.80 | +212.93% | 5 | Jun 20, 2024 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $10 | $1.00 | +900.00% | 4 | May 12, 2023 | |
| ALLK Allakos | Maintains: Buy | $145 → $155 | $0.33 | +46,926.70% | 2 | Dec 13, 2021 |
Cytokinetics
Apr 15, 2025
Maintains: Neutral
Price Target: $62 → $54
Current: $32.13
Upside: +68.07%
Insmed
Mar 20, 2025
Maintains: Buy
Price Target: $92 → $96
Current: $67.75
Upside: +41.70%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $8.80
Upside: +93.18%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $6.09
Upside: +376.58%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $10.99
Upside: +182.07%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $0.80
Upside: +212.93%
Werewolf Therapeutics
May 12, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $1.00
Upside: +900.00%
Allakos
Dec 13, 2021
Maintains: Buy
Price Target: $145 → $155
Current: $0.33
Upside: +46,926.70%